Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors

被引:53
作者
Al Koudsi, Nael [2 ]
Hoffmann, Ewa B. [2 ,3 ]
Assadzadeh, Abbas [2 ]
Tyndale, Rachel F. [1 ,3 ]
机构
[1] Univ Toronto, Dept Pharmacol & Toxicol & Psychiat, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A8, Canada
[3] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada
关键词
CYP2A6; Nicotine; Pharmacogenetics; Age; Gender; HUMAN LIVER-MICROSOMES; C-OXIDATION; POLYMORPHIC ALLELES; CYTOCHROME-P450; EXPRESSION; VARIABILITY; METHYLATION; RECEPTOR; SMOKING;
D O I
10.1007/s00228-009-0762-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We investigated the role of genetic, physiological, environmental, and epigenetic factors in regulating CYP2A6 expression and nicotine metabolism. Human livers (n = 67) were genotyped for CYP2A6 alleles and assessed for nicotine metabolism and CYP2A6 expression (mRNA and protein). In addition, a subset of livers (n = 18), human cryopreserved hepatocytes (n = 2), and HepG2 cells were used for DNA methylation analyses. Liver samples with variant CYP2A6 alleles had significantly lower CYP2A6 protein expression, nicotine C-oxidation activity, and affinity for nicotine. Female livers had significantly higher CYP2A6 protein and mRNA expression compared to male livers. Livers exposed to dexamethasone and phenobarbital had higher CYP2A6 expression and activity, however the difference was not statistically significant. Age and DNA methylation status of the CpG island and a regulatory site were not associated with altered CYP2A6. We identified genotype, gender, and exposure to inducers as sources of variation in CYP2A6 expression and activity, but much variation remains to be accounted for.
引用
收藏
页码:239 / 251
页数:13
相关论文
共 43 条
[1]   Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics [J].
Al Koudsi, Nael ;
Mwenifumbo, Jill C. ;
Sellers, Edward M. ;
Benowitz, Neal L. ;
Swan, Gary E. ;
Tyndale, Rachel F. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) :481-484
[2]   A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo [J].
Al Koudsi, Nael ;
Ahluwalia, Jasjit S. ;
Lin, Shih-Ku ;
Sellers, Edward M. ;
Tyndale, Rachel F. .
PHARMACOGENOMICS JOURNAL, 2009, 9 (04) :274-282
[3]   Female sex and oral contraceptive use accelerate nicotine metabolism [J].
Benowitz, Neal L. ;
Lessov-Schlaggar, Christina N. ;
Swan, Gary E. ;
Jacob, Peyton, III .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (05) :480-488
[4]   Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics [J].
Benowitz, Neal L. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2009, 49 :57-71
[5]   METABOLISM OF NICOTINE TO COTININE STUDIED BY A DUAL STABLE-ISOTOPE METHOD [J].
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (05) :483-493
[6]   BiQ analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing [J].
Bock, C ;
Reither, S ;
Mikeska, T ;
Paulsen, M ;
Walter, J ;
Lengauer, T .
BIOINFORMATICS, 2005, 21 (21) :4067-4068
[7]  
CAMPBELL ME, 1987, DRUG METAB DISPOS, V15, P237
[8]   Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation [J].
Dannenberg, Luke O. ;
Edenberg, Howard J. .
BMC GENOMICS, 2006, 7 (1)
[9]   Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity [J].
Fukami, T ;
Nakajima, M ;
Higashi, E ;
Yamanaka, H ;
Sakai, H ;
McLeod, HL ;
Yokoi, T .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (08) :1202-1210
[10]   Pharmacoepigenetics: Its Role in Interindividual Differences in Drug Response [J].
Gomez, A. ;
Ingelman-Sundberg, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (04) :426-430